Table 3: Cohort
study: Post-index differences by depression/anxiety.
|
|
Total |
COPD
with Depression/Anxiety |
COPD
without Depression/Anxiety |
|
|||
|
|
N |
% |
N |
% |
N |
% |
Difference,
P
value † |
|
Number
of Patients |
31,279 |
100.00% |
12,701 |
100.00% |
18,578 |
100.00% |
|
|
Drugs Post-Index (N, % with any fills) |
|||||||
|
Antibiotics |
15,913 |
50.87% |
7,493 |
59.00% |
8,420 |
45.32% |
<
0.0001 |
|
ICS/LABA combination |
6,110 |
19.53% |
2,419 |
19.05% |
3,691 |
19.87% |
0.0718 |
|
Inhaled cortico-steroid (ICS) |
2,118 |
6.77% |
934 |
7.35% |
1,184 |
6.37% |
0.0007 |
|
Injected Steroids |
96 |
0.31% |
68 |
0.54% |
28 |
0.15% |
<
0.0001 |
|
Ipratropium |
4,578 |
14.64% |
2,165 |
17.05% |
2,413 |
12.99% |
<
0.0001 |
|
Long-acting
beta-agonist (LABA) |
719 |
2.30% |
290 |
2.28% |
429 |
2.31% |
0.8807 |
|
Leukotriene Modifiers |
2,817 |
9.01% |
1,237 |
9.74% |
1,580 |
8.50% |
0.0002 |
|
Methylxanthines |
1,216 |
3.89% |
510 |
4.02% |
706 |
3.80% |
0.3335 |
|
Oral cortico-steroids (OCS) |
6,294 |
20.12% |
2,871 |
22.60% |
3,423 |
18.43% |
<
0.0001 |
|
Short-acting
beta-agonist (SABA) |
6,578 |
21.03% |
2,907 |
22.89% |
3,671 |
19.76% |
<
0.0001 |
|
Tiotropium |
4,470 |
14.29% |
1,657 |
13.05% |
2,813 |
15.14% |
<
0.0001 |
|
any of above drugs* |
23,103 |
73.86% |
9,978 |
78.56% |
13,125 |
70.65% |
<
0.0001 |
|
Utilization (N, % with any event) |
|||||||
|
Moderate Exacerbation |
2,821 |
9.02% |
1,396 |
10.99% |
1,425 |
7.67% |
<
0.0001 |
|
Severe Exacerbation |
587 |
1.88% |
318 |
2.50% |
269 |
1.45% |
<
0.0001 |
|
Utilization (Mean events, SD) |
|||||||
|
Moderate Exacerbation |
0.10 |
(0.31) |
0.12 |
(0.34) |
0.08 |
(0.29) |
<
0.0001 |
|
Severe Exacerbation |
0.02 |
(0.15) |
0.03 |
(0.17) |
0.02 |
(0.13) |
<
0.0001 |
SD: standard
deviation
*use of
omalizumab and mast cell stabilizers are also included but not reported because
of cell size report restrictions
†p-values
are calculated using chi-square test for frequency differences and t-test for
mean differences